A new anti-fungal treatment is to appear on the markets of Russia, the C.I.S., and Turkey as a result of collaborative efforts between Rus­sia’s R-Pharm and Scynexis from the United States. The two companies plan to develop, register, and market the new effective remedy. The agreement between the companies for the deal has already been reached.

The U.S.-based Scynexis, which is located in North Carolina, will retain the rights for sell­ing the new drug on the American, European, and Asian markets. Scynexis will also have the rights for royalty payments from the commer­cialization of this medication.

The president of Scynexis Yves Ribeill ap­plauded the company’s partnership with R- Pharm, noting that the venture is bound to give the American company access to various important markets with high potential.